October 13, 2021 5:45pm

Up, down, round and round

Pre-open indication results: 5 Hits and 1 MISS

My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close

An objective, fact and numbers-based narrative

The Dow closed DOWN -0.53 points (-0.00%); the S&P closed UP +13.15 points (+0.30%) while the Nasdaq closed UP +105.71 points (+0.73%)

 

Henry’omics:

The Dow dived, the Nasdaq popped while the S&P 500 snapped a three-day losing streak Wednesday as investors digested Q/3 earnings and insights into when the Fed might taper its asset-purchase program

Minutes released Wednesday afternoon from the Federal Open Market Committee’s September meeting showed the central bank could begin tapering its asset-purchase program as soon as mid-November.

 

Economic Data Docket: The September consumer price index released Wednesday morning jumped 0.4% in September from the month prior and 5.4% year over year, according to the Labor Department. Economists expected to see a month-to-month increase of 0.3% or annualized rate of 5.3%. Excluding energy and food, the core CPI rose 0.2% month over month and 4% over the last 12 months, against respective estimates for 0.3% and 4%.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Wednesday opened positive at 21/13 and 1 acquired, strayed neutral at the mid-day at 17/17 and 1 acquired, ending with a positive close of 19/14, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “mixed sector vibes” … https://www.regmedinvestors.com/articles/12136

 

Pre-open indication results: 5 Hits: <Ionis Pharmaceuticals (IONS -$0.45); SELL into Strength:  BioLife Solutions (BLFS -$0.42), Fate Therapeutics (FATE +$1.08), Homology Medicine (FIXX -$0.37), ReNeuron (RENE.L -$6.00)> and 1 MISS < Biostage (BSTG +$0.09 – “pumped” with 3,492 share traded after 600 shares traded Tuesday and 0 on Monday),

 

Key Metric - volume:

  • Sector volume was LOW with 2 of the19-upside having higher than the 3-month average volume with INCREASED volume of 5 of 14-downside having higher than the 3-month average volume;

Largest upside volume:

  • Voyager Therapeutics (VYGR +$0.08 – 3.762 m shares traded)

Largest downside volume:

  • CRISPR Therapeutics (CRSP -$5.82 – 6.418 m shares traded)

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 19):

  • Vericel (VCEL +$1.16 after Tuesday’s -$1.46 and Monday’s -$1.48)
  • Fate Therapeutics (FATE +$1.08 after Tuesday’s +$2.52 and Monday’s +$1.62)
  • Global Blood Therapeutics (GBT +$0.63 after Tuesday’s +$1.07 and Monday’s +$0.70),
  • Cellectis SA (CLLS +$0.47),
  • Alnylam Pharmaceuticals (ALNY +$0.45 after Tuesday’s -$1.09 and Monday’s +$0.83)
  • BioLife Solutions (BLFS +$0.42 after Tuesday’s +$0.59 and Monday’s -$0.52)
  • Editas Medicine (EDIT +$0.34 and Tuesday’s +$0.89),
  • MiMedx (MDXG +$0.16),
  • Pluristem (PSTI =$0.03 after Tuesday’s -$0.04),
  • Sangamo Therapeutics (SGMO +$0.12 after Tuesday’s -$0.08),

Hammered in today’s market (10 of 14):

  • ReNeuron (RENE.L -$6.00 after Tuesday’s +$2.50 and Monday’s +$20.70)
  • CRISPR Therapeutics (CRSP -$5.82 after Tuesday’s +$1.94 and Monday’s +$2.02),
  • Intellia therapeutics (NTLA -$2.73 after Tuesday’s +$2.15 and Monday’s +$5.22),
  • Ultragenyx (RARE -$1.71 after Tuesday’s +$1.80 and Monday’s -$0.65),
  • Regenxbio (RGNX -$0.45 after Tuesday’s +$2.35 and Monday’s +$1.94),
  • Ionis Pharmaceuticals (IONS -$0.45 after Tuesday’s -$0.40 and Monday’s +$0.32),
  • Homology Medicine (FIXX -$0.37),
  • bluebird bio (BLUE -$0.31 after Tuesday’s +$0.53 and Monday’s +$0.80),
  • uniQure NV (QURE -$0.29),
  • AxoGen (AXGN -$0.25 after Tuesday’s -$0.02 and Monday’s -$0.09),

Closing Flat:

1 – Applied Genetic Technologies (AGTC), and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday the IBB closed up +0.58% and XBI closed up +0.42%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -1.21 points or -6.10% at 18.64

 

October, the first month of Q3/21:

Wednesday closed positive with 19 advancers, 14 decliners, 1 flat and 1 acquired

Tuesday closed positive with 21 advancers, 14 decliners, 2 flats and 1 acquired

Monday (10/11) closed positive with 19 advancers, 14 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: Coming, EPS (earnings-per-share) risk; but, eyeing muted returns for the rest of 2021 re quarterly releases.

 I’m still welcoming the upside but, warn of “harm” coming to share pricing.

Once again, a large number of stem, cell and gene therapy stocks showed strength within a lackluster market at best.

There are a lot of headwinds out there as we embark on corporate earnings, and traders will be looking for any and all indications of guidance.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.